Suppr超能文献

慢性HIV-1感染中细胞毒性T淋巴细胞逃逸突变体出现的等待时间。

Waiting times for the appearance of cytotoxic T-lymphocyte escape mutants in chronic HIV-1 infection.

作者信息

Liu Yi, Mullins James I, Mittler John E

机构信息

Department of Microbiology, University of Washington School of Medicine, Seattle, WA, 98195-8070, USA.

出版信息

Virology. 2006 Mar 30;347(1):140-6. doi: 10.1016/j.virol.2005.11.036. Epub 2006 Jan 4.

Abstract

The failure of HIV-1 to escape at some cytotoxic T-lymphocyte (CTL) epitopes has generally been explained in terms of viral fitness costs or ineffective or attenuated CTL responses. Relatively little attention has been paid to the evolutionary time required for escape mutants to be detected. This time is significantly affected by selection, mutation rates, the presence of other advantageous mutations, and the effective population size of HIV-1 in vivo (typically estimated to be approximately 10(3) in chronically infected patients, though one study has estimated it to be approximately 10(5)). Here, we use a forward simulator with experimentally estimated HIV-1 parameters to show that these delays can be substantial. For an effective population size of 10(3), even highly advantageous mutants (s = 0.5) may not be detected for a couple of years in chronically infected patients, while moderately advantageous escape mutants (s = 0.1) may not be detected for up to 10 years. Even with an effective population size of 10(5), a moderately advantageous escape mutant (s = 0.1) may not be detected in the population within 2 years if it has to compete with other selectively advantageous mutants. Stochastic evolutionary forces, therefore, in addition to viral fitness costs and ineffective or attenuated CTL responses, must be taken into account when assessing the selection of CTL escape mutations.

摘要

HIV-1未能在某些细胞毒性T淋巴细胞(CTL)表位处逃逸,通常被解释为病毒适应性成本、无效或减弱的CTL反应。相对而言,人们很少关注检测到逃逸突变体所需的进化时间。这段时间受到选择、突变率、其他有利突变的存在以及体内HIV-1有效种群大小的显著影响(在慢性感染患者中,通常估计约为10³,不过一项研究估计约为10⁵)。在这里,我们使用一个具有实验估计的HIV-1参数的正向模拟器来表明,这些延迟可能相当大。对于有效种群大小为10³的情况,即使是高度有利的突变体(s = 0.5),在慢性感染患者中几年内也可能检测不到,而中度有利的逃逸突变体(s = 0.1)可能长达10年都检测不到。即使有效种群大小为10⁵,如果中度有利的逃逸突变体(s = 0.1)必须与其他具有选择优势的突变体竞争,那么在两年内也可能无法在种群中检测到。因此,在评估CTL逃逸突变的选择时,除了病毒适应性成本和无效或减弱的CTL反应外,还必须考虑随机进化力量。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验